Healthcare

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UW spinout Nicoya has its sight set on product development and business expansion after a series A round featuring UW Student Venture Fund and Wilfrid Laurier University’s Startup Fund.

Ian Postlethwaite will exit as CEO of NetScientific this July as the embattled commercialisation firm continues to patch up its balance sheet.

University of Pittsburgh Medical Center’s venture arm has allocated $1bn to drugs, diagnostics and devices development, including a $200m partnership with the university.

Treadwell has launched with seed funding from Tio Bioventures to commercialise small molecule cancer drugs based on University Health Network research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.